<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638439</url>
  </required_header>
  <id_info>
    <org_study_id>A20-101</org_study_id>
    <nct_id>NCT04638439</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection</brief_title>
  <official_title>A Phase Ib, Open Label Study to Assess the Safety and Efficacy of Sequential Administration of P1101 and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaEssentia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaEssentia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To evaluate the safety and tolerability of sequential administration of P1101 and anti-PD1 in&#xD;
      patient with chronic hepatitis B or D infection&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To explore HBsAg loss and kinetics during the study period&#xD;
&#xD;
        2. To assess the anti-viral effect during the study period&#xD;
&#xD;
        3. To evaluate the rate of ALT normalization&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 20 scheduled visits (screening, treatment weeks &amp; follow-up weeks) for patients&#xD;
      with &gt; 0.5 log10 decline in HBsAg at TW12, which include screening visit, TW0 (baseline),&#xD;
      TW2, TW4, TW6, TW8, TW10, TW12, TW13, TW15, TW17, TW19, TW21, TW23 (EOT), FW4, FW8, FW12,&#xD;
      FW16, FW20 and FW24.&#xD;
&#xD;
      There are 22 scheduled visits for patients with ≤ 0.5 log10 decline in HBsAg at TW12. These&#xD;
      visits include screening visit, TW0 (baseline), TW2, TW4, TW6, TW8, TW10, TW12, TW13, TW16,&#xD;
      TW17, TW19, TW21, TW23, TW25, TW27 (EOT), FW4, FW8, FW12, FW16, FW20 and FW24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: AE/SAE</measure>
    <time_frame>Through study Follow-up Week 24 (up to 330 or 358 days)</time_frame>
    <description>Number of patients with adverse events, including SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: clinically significant abnormalities</measure>
    <time_frame>Through study Follow-up Week 24 (up to 330 or 358 days)</time_frame>
    <description>Number of patients with clinically significant abnormalities, including vital sign, physical examination, electrocardiogram (ECG) and laboratory data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects with HBsAg loss</measure>
    <time_frame>Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24</time_frame>
    <description>The percentage of subjects with HBsAg loss at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with HBsAg reduction from baseline</measure>
    <time_frame>Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24</time_frame>
    <description>The percentage of subjects with HBsAg reduction from baseline at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with HBsAg seroconversion</measure>
    <time_frame>Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24</time_frame>
    <description>The percentage of subjects with HBsAg seroconversion at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with undetectable HBV DNA</measure>
    <time_frame>Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24</time_frame>
    <description>The percentage of subjects with undetectable HBV DNA at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with ≥ 2 log10 decline from baseline in HDV RNA</measure>
    <time_frame>Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24</time_frame>
    <description>The percentage of subjects with ≥ 2 log10 decline from baseline in HDV RNA at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with undetectable HDV RNA</measure>
    <time_frame>Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24</time_frame>
    <description>The percentage of subjects with undetectable HDV RNA at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with ALT normalization</measure>
    <time_frame>Treatment Week 12, Treatment Week 23 or 27, Follow-up Week 12 and Follow-up Week 24</time_frame>
    <description>The percentage of subjects with ALT normalization at treatment week 12, 23/27 and follow up week 12, 24 in the treatment group</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Hepatitis B Infection</condition>
  <condition>Chronic Hepatitis D Infection</condition>
  <arm_group>
    <arm_group_label>P1101 + Nivolumab + Entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P1101 + Nivolumab + Entecavir</intervention_name>
    <description>P1101 (Ropeginterferon alfa-2b) 450 µg subcutaneously (SC) Q2W for 6 doses (12 weeks) *, followed by 0.3 mg/kg Nivolumab for 6 doses (12 weeks) **, with a follow up of 24 weeks. All patients will also receive Entecavir 0.5 mg QD from Day 1 to Follow-up 24.&#xD;
*: HBsAg will be checked at treatment week 12 (or 16, if applicable).&#xD;
**: Only patients with &gt; 0.5 log10 decline in HBsAg at treatment week 12 or 16 will be sequentially treated with Anti-PD1.</description>
    <arm_group_label>P1101 + Nivolumab + Entecavir</arm_group_label>
    <other_name>P1101 (Ropeginterferon alfa-2b) + Nivolumab + Entecavir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Positive for HBsAg for at least 6 months, either HBeAg (+) or HBeAg (-), and ALT ≥ULN&#xD;
             to ≤ 10X ULN at screening;&#xD;
&#xD;
          2. Interferon naïve;&#xD;
&#xD;
          3. Quantitative HBsAg Level &lt; 1,500 IU/mL at screening; Undetectable HBV DNA (either&#xD;
             under NUC treatment or not)&#xD;
&#xD;
          4. Adults ≥20 years of age; patients who are over 70 years of age must be in generally&#xD;
             good health depending upon the Investigator's judgment;&#xD;
&#xD;
          5. Laboratory test results before study entry: WBC ≥ 3,000/mm3; ANC ≥ 1,500/mm3; Platelet&#xD;
             ≥ 90,000/mm3; Hemoglobin ≥ 10g/dL; e-GFR ≥ 60mL/min;&#xD;
&#xD;
          6. ECG without clinically significant abnormalities before study entry;&#xD;
&#xD;
          7. Be able to attend all scheduled visits and to comply with all study procedures;&#xD;
&#xD;
          8. Patients with anti-HDV (+) can be enrolled;&#xD;
&#xD;
          9. Patients with fibrosis stage &lt; F4 can be enrolled;&#xD;
&#xD;
         10. Willing to provide written informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant illness or surgery that might interfere with study&#xD;
             participation;&#xD;
&#xD;
          2. Clinically significant vital sign abnormalities or fever [body temperature &gt;38℃]);&#xD;
&#xD;
          3. History of significant alcohol or drug abuse within 6 months prior to the screening&#xD;
             visit (alcohol consumption of more than 14 units of alcohol per week [1 Unit = 150 mL&#xD;
             of wine, 360 mL of beer, or 45 mL of 40% alcohol]) or refusal to abstain from alcohol&#xD;
             or illicit drugs throughout the study;&#xD;
&#xD;
          4. Any history or presence of poorly controlled or clinically significant medical&#xD;
             conditions that are not suitable to receive interferon-based treatment, at the&#xD;
             discretion of the investigator: major psychiatric (including but not limited to those&#xD;
             with severe depression, severe bi-polar disorder, schizophrenia, suicidal ideation or&#xD;
             history of suicidal attempt), neurological, cardiovascular (i.e. uncontrolled&#xD;
             hypertension, congestive heart failure (≥ NYHA class 2), serious cardiac arrhythmia,&#xD;
             significant coronary artery stenosis, unstable angina) or recent stroke or myocardial&#xD;
             infarction), pulmonary, hematologic, immunologic, autoimmune diseases, thyroid or&#xD;
             other endocrine diseases, metabolic (e.g. diabetes mellitus with HbA1C &gt; 8.0%) or&#xD;
             other uncontrolled systemic disease, coagulation disorders or blood dyscrasias;&#xD;
&#xD;
          5. Pregnant patient, female patient or the spouse of male patient, with child-bearing&#xD;
             potential who is unwilling or unable to practice adequate contraception, defined as&#xD;
             vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth&#xD;
             control pills, or intrauterine devices throughout the study;&#xD;
&#xD;
          6. History of severe allergic or hypersensitivity reactions, e.g. hypersensitivity to the&#xD;
             active substance or to any of the excipients of Ropeginterferon alfa-2b (P1101),&#xD;
             bronchospasm, angioedema, asthma, or anaphylaxis;&#xD;
&#xD;
          7. Therapy with any systemic anti-viral treatment, anti-neoplastic, or immunomodulatory&#xD;
             treatment (including supraphysiologic doses of steroids and radiation) within 1 month&#xD;
             (3 months for those with long elimination half-lives) prior to the first dose of study&#xD;
             drug;&#xD;
&#xD;
          8. A depot injection or an implant of any drug within 3 months prior to administration of&#xD;
             study medication, other than contraception or hyaluronic acid injections in joints for&#xD;
             osteoarthritis;&#xD;
&#xD;
          9. Body organ transplant or taking immunosuppressant;&#xD;
&#xD;
         10. Use investigational drug of other clinical trials within 4 weeks prior to the first&#xD;
             dose of the study drug;&#xD;
&#xD;
         11. History of malignancy diagnosed or treated within 5 years prior to screening (except&#xD;
             for localized treatment of squamous or non-invasive basal cell skin cancers; cervical&#xD;
             carcinoma in situ);&#xD;
&#xD;
         12. History of opportunistic infection (e.g., invasive candidiasis or pneumocystis&#xD;
             pneumonia);&#xD;
&#xD;
         13. Serious localized infection (e.g., cellulitis, abscess) or systemic and&#xD;
             life-threatening infection (e.g., septicemia) within 3 months prior to screening;&#xD;
&#xD;
         14. Clinically significant medical conditions known to interfere absorption, distribution,&#xD;
             metabolism or excretion of the study drugs;&#xD;
&#xD;
         15. Decompensated liver disease, which includes but not limited to the following: total&#xD;
             bilirubin≥2 mg/dL (except in Gilbert syndrome), direct bilirubin ≥2X ULN, albumin&#xD;
             level &lt; 3.5 g/dL, INR ≥1.5; clinical evidence of ascites, liver decompensation,&#xD;
             hepatic encephalopathy, oesophageal varices or cirrhosis as identified by ultrasound&#xD;
             or any other examination before study entry;&#xD;
&#xD;
         16. Significant steatohepatitis by ultrasound or other examination at the discretion of&#xD;
             investigator;&#xD;
&#xD;
         17. Other form of significant chronic liver diseases, except those mentioned above (e.g.&#xD;
             HBV, HDV);&#xD;
&#xD;
         18. Significant or major fundoscopic findings at screening including but not limited to&#xD;
             retinal exudates, hemorrhage, detachment, neovascularization, papilledema, optic&#xD;
             atrophy, microaneurysms and macular changes;&#xD;
&#xD;
         19. Positive for anti-HIV or anti-HCV;&#xD;
&#xD;
         20. Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4&#xD;
             antibody, or any other antibody or drug specifically targeting T-cell co-stimulation&#xD;
             or immune checkpoint pathway;&#xD;
&#xD;
         21. Any contraindication to receiving anti-PD-1 antibody (e.g. active or a history of&#xD;
             life-threatening autoimmune conditions, corticosteroids treatment required) or&#xD;
             hypersensitivity to the constituents of anti-PD-1 antibody;&#xD;
&#xD;
         22. Patients under monotherapy by telbivudine or any other combination therapy with&#xD;
             telbivudine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wendy Hung, MS</last_name>
    <phone>+886-2-2655-7688</phone>
    <phone_ext>1397</phone_ext>
    <email>Wanchu_Hung@pharmaessentia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erwin Teng, MS</last_name>
    <phone>+886-2-2655-7688</phone>
    <phone_ext>1374</phone_ext>
    <email>erwin_teng@pharmaessentia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei city</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi-Wen Huang, Ph.D.</last_name>
      <email>yiwenhuang@tmu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei city</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Linkou</name>
      <address>
        <city>Taoyuan city</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P1101</keyword>
  <keyword>Anti-PD1</keyword>
  <keyword>HBV</keyword>
  <keyword>HDV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis D, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

